Mainz Biomed announces a strategic partnership in Italy for ColoAlert®

Mainz Biomed N.V., a leader in genetic molecular diagnostics for early cancer detection, has announced a strategic partnership with TomaLab to launch ColoAlert® in Italy. TomaLab, based in Milan, is renowned in the biotechnology field. This partnership represents a significant advancement for colorectal cancer screening and diagnosis in the Italian healthcare system, providing access to cutting-edge diagnostic solution.

ColoAlert®, a non-invasive home screening test, utilizes advanced DNA technology to accurately detect cancerous and precancerous conditions. The tool is crucial in combating one of the most common and deadliest cancers, especially given the rising rates of colorectal cancer among young adults in Italy. With its advanced diagnostic capabilities, ColoAlert® aims to improve early detection rates and hence, survival chances.

The collaboration underscores Mainz Biomed and TomaLab's commitment to healthcare innovation, aiming to enhance patient care and outcomes. ColoAlert® is already marketed in some EU countries, and Mainz Biomed is conducting a crucial clinical study for FDA regulatory approval in the United States.